Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - KRAS
 More »

  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    The firm said that activating mutations in KRAS (beyond exon 2) and mutations in ... survival among patients with wild-type KRAS exon 2 metastatic colorectal cancer ...
    5-16-2013
  • Amgen Forms Joint Venture to Sell Vectibix in China
    that Vectibix was at least as effective as rival drug Erbitux (cetuximab), marketed by Eli Lilly and Merck Serono, as a single agent for mCRC patients with wild-type KRAS tumors. ...
    5-10-2013
  • Companion Diagnostics: 52 Pick-Up
    ... treatment is being considered. therascreen KRAS RGQ PCR Kit Sponsor/Developer: Qiagen ... of seven somatic mutations in the human KRAS oncogene, using DNA extracted from FFPE ...
    5-9-2013
  • Detecting Acquired Drug Resistance in Cancer
    ... They had previously reported that KRAS mutant alleles emerged in the circulation of ... In a new approach Siravegna and colleagues had a look at the 50% of patients in which KRAS ...
    4-29-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    ... oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy Date of FDA approval: September 27, 2012 #6. ...
    4-4-2013
  • Women and Smoking
    ... 19 deletions and L858R) and KRAS (G12, G13) examining correlations with demographic, clinical, and smoking history data. The researchers focused on KRAS, which is frequently ...
    4-3-2013
  • Development and Evolution of PCR
    ... genetic targets, such as cystic fibrosis carrier screening, and many focus on detecting inherited (e.g., BRACA1 and BRACA2) mutations and somatic mutations in tumors (e.g., KRAS). ...
    4-1-2013
  • Advertorial: Swift Biosciences
    ... Swift has developed myT Primers for the common mutations in BRAF and KRAS genes to demonstrate the superior performance capabilities of the technology for mutation detection. ...
    4-1-2013
  • Personalized Medicine: From Biomarkers to Companion Diagnostics
    A number of biomarkers, such as KRAS and EGFR mutations, could only be established after a ... were asked to select patients with a positive EGFR biomarker or a KRAS biomarker. ...
    3-26-2013
  • Personalized Medicine: Translation of Concepts
    Examples include Her-2/neu (Trastuzumab/Lapatinib), KRAS (Cetuximab/Panitumomab), BRAF (Vemurafenib), and CCR5 (Maraviroc). We Lack Model Systems to Predict Drug Response In our ...
    3-19-2013
  • Molecular Characterization of CTCs
    ... Figure 3. KRAS mutation detection in colorectal cancer patients. qPCR readouts identify a ... As one example, Fluxion has developed a sensitive KRAS mutation detection panel for use ...
    3-15-2013
  • Lab21, IntegraGen Aim to SPARQ New Cancer Diagnostic
    response to EGFR inhibitor therapy in KRAS wild-type patients who have metastatic ... stratified by determining mutations in the KRAS gene, the companies say that microRNA ...
    2-22-2013
  • Use of Digital PCR Ramping Up
    ... For example, one of RainDance Technologies' early users was able to detect a single mutated copy of KRAS in a background of 200,000 wild-type KRAS copies, claimed Dr. Link. "When ...
    2-15-2013
  • Unlocking Biomarkers' Full Potential
    ... For example, EGFR measures the level of receptor expression; Braf and Kras markers measure the presence of the mutation and translocation in the ALK gene measures gene knockout. It ...
    2-1-2013
  • Improving Molecular Genetic Testing
    Building a New Standard Figure 1. Reference materials are available from Horizon Diagnostics in gDNA and FFPE formats. Key mutations are shown for EGFR, KRAS, PI3K, and BRAF. Other ...
    12-1-2012
  • More »

    Journal Articles

  • Molecular, Morphologic, and Outcome Analysis of Thyroid Carcinomas...
    Michael Rivera, Julio Ricarte-Filho, Robert Michael Tuttle, Ian Ganly, Ashok Shaha, Jeffrey Knauf, James Fagin, Ronald Ghossein
    Thyroid
    Cases with paraffin tissues were subjected to mass spectrometry genotyping encompassing the most significant oncogenes in TC: 111 mutations in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, ...
  • Prevalence, Clinicopathologic Features, and Somatic Genetic Mutation...
    Willieford Moses, Julie Weng, Electron Kebebew
    Thyroid
    Thyroid nodule fine-needle aspiration biopsy samples and tumor tissue at the time of thyroidectomy were used to test for somatic genetic mutations (BRAF V600E, NRAS, KRAS, NTRK1, ...
  • A Novel Polymorphism in Codon 25 of the KRAS Gene Associated...
    Vishmadeb Pramanik, Biswanath N. Sarkar, Madhuchanda Kar, Gautam Das, Barman K. Malay, Khannam K. Sufia, Bhaskar V.K.S. Lakkakula, Rao R. Vadlamudi
    Genetic Testing and Molecular Biomarkers
    A Novel Polymorphism in Codon 25 of the KRAS Gene Associated with Gallbladder Carcinoma ... could be of importance in this regard. KRAS is the most frequently mutated member and ...
  • Molecular Genetics External Quality Assessment Pilot Scheme for...
    Zandra C. Deans, Justyna Tull, Gemma Beighton, Stephen Abbs, David O. Robinson, Rachel Butler
    Genetic Testing and Molecular Biomarkers
    Molecular Genetics External Quality Assessment Pilot Scheme for KRAS Analysis in ... for the detection of mutations in the KRAS gene in metastatic colorectal cancers to ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll